EU-OPENSCREEN: A Novel Collaborative Approach to Facilitate Chemical Biology
暂无分享,去创建一个
J. Mestres | S. Krauss | J. Brea | P. Brennecke | A. Jirgensons | A. Pineda-Lucena | P. Zielenkiewicz | Aurora Martínez | B. Cautain | F. Vicente | K. Taskén | K. Paruch | M. Vicent | Bahne Stechmann | O. Genilloud | Johannes Landskron | P. Bartůněk | U. Bilitewski | M. Clausen | J. H. Andersen | E. Hansen | Luca Laraia | H. Lickert | M. Brönstrup | J. V. von Kries | M. Nazaré | J. Quintana | M. Neuenschwander | Jacek L Kolanowski | L. Lehtiö | B. Ellinger | M. Orzáez | E. Specker | R. Pilarski | W. Fecke | P. Gribbon | Oscar Aubi | Z. Leśnikowski | D. Rasina | Katja Herzog | Faranak Nami | Šárka Šímová
[1] Aurora Martínez,et al. Early Stage Discovery and Validation of Pharmacological Chaperones for the Correction of Protein Misfolding Diseases. , 2018, Methods in molecular biology.
[2] B. Merinero,et al. New perspectives for pharmacological chaperoning treatment in methylmalonic aciduria cblB type. , 2018, Biochimica et biophysica acta. Molecular basis of disease.
[3] Stefan Krauss,et al. Discovery of a Novel Series of Tankyrase Inhibitors by a Hybridization Approach. , 2017, Journal of medicinal chemistry.
[4] Aurora Martínez,et al. Conformational stabilization as a strategy to prevent nucleophosmin mislocalization in leukemia , 2017, Scientific Reports.
[5] Kenji Schorpp,et al. A high-content small molecule screen identifies novel inducers of definitive endoderm , 2017, Molecular metabolism.
[6] Aurora Martínez,et al. Pharmacological Chaperoning: A Potential Treatment for PMM2‐CDG , 2017, Human mutation.
[7] D. Leonoudakis,et al. A high throughput drug screening assay to identify compounds that promote oligodendrocyte differentiation using acutely dissociated and purified oligodendrocyte precursor cells , 2016, BMC Research Notes.
[8] Adrian J. Verster,et al. High-Content Screening for Quantitative Cell Biology. , 2016, Trends in cell biology.
[9] J. Luke,et al. Correlation of WNT/β-catenin pathway activation with immune exclusion across most human cancers. , 2016 .
[10] L. Federici,et al. Molecules that target nucleophosmin for cancer treatment: an update , 2016, Oncotarget.
[11] K. O'Byrne,et al. Drug Discovery Approaches Utilizing Three-Dimensional Cell Culture. , 2016, Assay and drug development technologies.
[12] E. Parmee,et al. The Impact of Chemical Probes in Drug Discovery: A Pharmaceutical Industry Perspective. , 2016, Cell chemical biology.
[13] A. Jirgensons,et al. Fragment-Based Discovery of 2-Aminoquinazolin-4(3H)-ones As Novel Class Nonpeptidomimetic Inhibitors of the Plasmepsins I, II, and IV. , 2016, Journal of medicinal chemistry.
[14] Aurora Martínez,et al. Discovery of a Specific Inhibitor of Pyomelanin Synthesis in Legionella pneumophila. , 2015, Journal of medicinal chemistry.
[15] Junjie Chen,et al. Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins. , 2015, Cell reports.
[16] N. Fernàndez-Castillo,et al. Discovery of compounds that protect tyrosine hydroxylase activity through different mechanisms. , 2015, Biochimica et biophysica acta.
[17] John P. Overington,et al. The promise and peril of chemical probes. , 2015, Nature chemical biology.
[18] M. Mondal,et al. Fighting malaria: structure-guided discovery of nonpeptidomimetic plasmepsin inhibitors. , 2015, Journal of medicinal chemistry.
[19] Leonor Puchades-Carrasco,et al. Fragment-based Drug Design Using NMR Methods , 2015 .
[20] Jonathan Hall,et al. Tankyrase 1 Inhibitors with Drug-like Properties Identified by Screening a DNA-Encoded Chemical Library. , 2015, Journal of medicinal chemistry.
[21] Jesús Martín,et al. Identification of the Lipodepsipeptide MDN-0066, a Novel Inhibitor of VHL/HIF Pathway Produced by a New Pseudomonas Species , 2015, PloS one.
[22] T. Gajewski,et al. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.
[23] Jordi Mestres,et al. Distant polypharmacology among MLP chemical probes. , 2015, ACS chemical biology.
[24] O. Genilloud,et al. Pseudomonas granadensis sp. nov., a new bacterial species isolated from the Tejeda, Almijara and Alhama Natural Park, Granada, Spain. , 2015, International journal of systematic and evolutionary microbiology.
[25] D. Melton,et al. Generation of Functional Human Pancreatic β Cells In Vitro , 2014, Cell.
[26] Dragos Horvath,et al. Design of a General‐Purpose European Compound Screening Library for EU‐OPENSCREEN , 2014, ChemMedChem.
[27] James D. Johnson,et al. Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells , 2014, Nature Biotechnology.
[28] J. Schiesser,et al. Generation of β cells from human pluripotent stem cells: Are we there yet? , 2014, Annals of the New York Academy of Sciences.
[29] R. Banerjee,et al. Pharmacological chaperones as a potential therapeutic option in methylmalonic aciduria cblB type. , 2013, Human molecular genetics.
[30] A. Muga,et al. Screening and evaluation of small organic molecules as ClpB inhibitors and potential antimicrobials. , 2013, Journal of medicinal chemistry.
[31] Steve Schneider,et al. Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors. , 2013, Journal of medicinal chemistry.
[32] Stephen W. Fesik,et al. Fragment-based drug discovery using NMR spectroscopy , 2013, Journal of biomolecular NMR.
[33] S. Krauss,et al. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. , 2013, Cancer research.
[34] A. Fallarero,et al. Screening and structural analysis of flavones inhibiting tankyrases. , 2013, Journal of medicinal chemistry.
[35] G. Drewes,et al. Structural basis and SAR for G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor. , 2013, Journal of medicinal chemistry.
[36] B. Cautain,et al. HCS strategy targeting dysregulation of the VHL/HIF pathway for drug discovery * , 2013 .
[37] Aurora Martínez,et al. Phenylalanine Hydroxylase Misfolding and Pharmacological Chaperones† , 2012, Current topics in medicinal chemistry.
[38] Jordi Mestres,et al. Identification of pim kinases as novel targets for PJ34 with confounding effects in PARP biology. , 2012, ACS chemical biology.
[39] G. Keller,et al. Generation of beta cells from human pluripotent stem cells: Potential for regenerative medicine. , 2012, Seminars in cell & developmental biology.
[40] H. Dinh,et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. , 2012, Cancer research.
[41] D. Goldberg,et al. Recent advances in plasmepsin medicinal chemistry and implications for future antimalarial drug discovery efforts. , 2012, Current topics in medicinal chemistry.
[42] A. Fallarero,et al. Homogeneous Screening Assay for Human Tankyrase , 2012, Journal of biomolecular screening.
[43] David J Newman,et al. Natural products as sources of new drugs over the 30 years from 1981 to 2010. , 2012, Journal of natural products.
[44] D. Chin,et al. [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding. , 2012, Journal of medicinal chemistry.
[45] L. Lehtiö,et al. Structural basis of selective inhibition of human tankyrases. , 2012, Journal of medicinal chemistry.
[46] Natalia Markova,et al. Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor. , 2010, Journal of medicinal chemistry.
[47] L. Gossage,et al. Alterations in VHL as potential biomarkers in renal-cell carcinoma , 2010, Nature Reviews Clinical Oncology.
[48] J. Baell,et al. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.
[49] P. Alonso,et al. New medicines to improve control and contribute to the eradication of malaria. , 2009, Nature reviews. Drug discovery.
[50] I. Burtscher,et al. Foxa2 regulates polarity and epithelialization in the endoderm germ layer of the mouse embryo , 2009, Development.
[51] P. Sutphin,et al. Targeted therapy for the loss of von Hippel-Lindau in renal cell carcinoma: A novel molecule that induces autophagic cell death , 2008, Autophagy.
[52] F. Diederich,et al. Structure-based drug design: exploring the proper filling of apolar pockets at enzyme active sites. , 2008, The Journal of organic chemistry.
[53] A. Velázquez‐Campoy,et al. Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. , 2008, The Journal of clinical investigation.
[54] P. Sutphin,et al. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. , 2008, Cancer cell.
[55] L. Serrano,et al. Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases. , 2007, American journal of human genetics.
[56] P. Sutphin,et al. Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells. , 2007, Cancer research.
[57] L. Prade,et al. Achiral, Cheap, and Potent Inhibitors of Plasmepsins I, II, and IV , 2006, ChemMedChem.
[58] Anders Hallberg,et al. Plasmepsins as potential targets for new antimalarial therapy , 2006, Medicinal research reviews.
[59] F. Diederich,et al. Starving the malaria parasite: inhibitors active against the aspartic proteases plasmepsins I, II, and IV. , 2006, Angewandte Chemie.
[60] J. D. Sharer. An Overview of Biochemical Genetics , 2005, Current protocols in human genetics.
[61] R. Rickert,et al. Hypoxia-Inducible Factor 1α Is Essential for Cell Cycle Arrest during Hypoxia , 2003, Molecular and Cellular Biology.
[62] Jun Liu,et al. Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[63] A. Kibel,et al. Tumour suppression by the human von Hippel-Lindau gene product , 1995, Nature Medicine.
[64] W. Linehan,et al. Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. , 1995, Seminars in oncology.
[65] M. Vicent,et al. Combined polymer-curcumin conjugate and ependymal progenitor/stem cell treatment enhances spinal cord injury functional recovery. , 2017, Biomaterials.
[66] Anders Hallberg,et al. Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity. , 2004, Journal of medicinal chemistry.
[67] R. Rickert,et al. Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. , 2003, Molecular and cellular biology.